Related Experiment Video
Updated: Feb 12, 2026

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
Published on: October 16, 2018
Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy
Jordan Gauthier1, Cameron J Turtle2
1Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
Abstract:
T-cells engineered to express CD19-specific chimeric antigen receptors (CD19 CAR-T cells) can achieve high response rates in patients with refractory/relapsed (R/R) CD19+ hematologic malignancies. Nonetheless, the efficacy of CD19-specific CAR-T cell therapy can be offset by significant toxicities, such as cytokine release syndrome (CRS) and neurotoxicity. In this report of our presentation at the 2018 Second French International Symposium on CAR-T cells (CAR-T day), we describe the clinical presentations of CRS and neurotoxicity in a cohort of 133 adults treated with CD19 CAR-T cells at the Fred Hutchinson Cancer Research Center, and provide insights into the mechanisms contributing to these toxicities.
Related Concept Videos
Cell Specific Gene Expression
Cell Specific Gene Expression
Gene Therapy
Energy-releasing Steps of Glycolysis
The first energy-releasing step—the 6th step of glycolysis...
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Group Therapy

